Reach Us +1-504-608-239
Defining the Role of a Novel Immune Checkpoint Modulator: Anti-OX40 | OMICS International
ISSN: 2577-0535
Journal of Cancer Clinical Trials

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Defining the Role of a Novel Immune Checkpoint Modulator: Anti-OX40

Sandrine Aspeslagh1* and Aurelien Marabelle1,2

1DITEP, Gustave Roussy Cancer Centre, Université Paris-Saclay, F-94805 Villejuif, France

2INSERM U1015, GRCC, F-94805 Villejuif, France

*Corresponding Author:
Sandrine Aspeslagh
DITEP, Gustave Roussy Cancer Centre
Université Paris-Saclay
F-94805 Villejuif, France
Tel: 33-4-6916-6595
E-mail: [email protected]

Received date: Jan 13, 2016; Accepted date: Jan 27, 2016; Published date: Feb 2, 2015

Citation: Aspeslagh S, Marabelle A (2016) Defining the Role of a Novel Immune Checkpoint Modulator: Anti-OX40. J Cancer Clin Trials 1:103. doi: 10.4172//jcct.1000103

Copyright: © 2016 Aspeslagh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Cancer Clinical Trials


The arrival of immune checkpoint blockers such anti-CTLA4 and anti-PD-L1/PD-L1 antibodies has again given hope to many cancer patients with advanced disease. Up to now its success has been demonstrated in more than 15 different cancer types. Tumor responses are durable, and translate into benefits in overall survival for patients. However as only around 20%-30% of patients show responses there is a huge need to find a durable solution for the other 70%-80% of patients. Massive efforts in preclinical research show that targeting activating costimulatory molecules such as OX40 or coinhibitory molecules such as LAG3 among others may also reduce cancer growth [1,3]. The major role of OX40 up regulation on a T cell is to improve the T-cell immune response after antigen recognition. This reaction can be boosted by agonistic anti-OX40 antibodies that are now moving to the clinic. Additionally these antibodies can deplete regulatory T cells and as such enhance native CD8 tumor response in mice. The first phase I study with anti-OX40 antibodies does indeed show a potent immune response but up to now no tumor response comparable to anti-PD-L1 antibodies. However anti-OX40 treatment was very well tolerated [2], and several combination trials have been setup to confirm the very strong preclinical results from tumor models in immunocompetent mice (eg NCT02205333). These mouse results show synergy especially between strategies that liberate tumor antigens such as radiotherapy, chemotherapy and surgery with anti-OX40. In these situations, anti- OX40 will boost the natural immune response and as such act as a very strong adjuvants to confer immunity against cancer antigens. Additionally a combination with anti-PD-L1 antibodies should be synergistic according to preclinical results [1]. Therefore results from combination trials with OX40 are highly awaited and will help us optimize novel immunotherapeutical possibilities.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 8732
  • [From(publication date):
    February-2016 - Sep 23, 2018]
  • Breakdown by view type
  • HTML page views : 8640
  • PDF downloads : 92

Review summary

  1. Pedro Araez
    Posted on Jul 20 2016 at 4:50 am
    The application of immune checkpoint blockers in cancer therapy is a major thrust area of research in the recent times. However, clinical trials of such blockers e.g. anti-CTLA4 and anti-PD-L1/PD-L1 antibodies showed positive response in only 20% of the cases. Further research showed that application of targeting co-stimulatory molecules such as OX40 with the help of Anti-OX40 antibodies can significantly reduce the progression of cancer. Combination of immune checkpoint blockers and co-stimulatory molecule blockers could help in the cure of cancer.

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

bornova escort

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7